Kevin Prescott1, Michael Jacobs1, Wendy Stock1, Joseph Wynne2. 1. Department of Medicine, University of Chicago Medicine, 900 E. 57th Street, 8th Floor, Chicago, IL, 60637, USA. 2. Department of Medicine, University of Chicago Medicine, 900 E. 57th Street, 8th Floor, Chicago, IL, 60637, USA. joseph.p.wynne@gmail.com.
Abstract
PURPOSE OF REVIEW: The treatment of acute lymphoblastic leukemia (ALL) in adolescent and young adult (AYA) patients has markedly improved with the adoption of pediatric-inspired protocols. However, there remain several subtypes of ALL that represent significant therapeutic challenges. Here, we review the current evidence guiding treatment of Philadelphia chromosome-positive (Ph+), Philadelphia chromosome-like (Ph-L), and early T-precursor (ETP) ALL in the AYA population. RECENT FINDINGS: Clinical trials in Ph + ALL have demonstrated the superior efficacy of second- and third-generation tyrosine kinase inhibitors (TKIs) to induce and maintain remission. Current efforts now focus on determining the durability of these remissions and which patients will benefit from transplant. For Ph-like and ETP ALL, recent studies are investigating the addition of novel agents to standard treatment. The treatment of Ph + ALL has significantly improved with the addition of potent TKIs. However, the treatment of Ph-like and ETP ALL remains a challenge. At this time, the judicious use of allogenic transplant is the only current approach to modify this increased risk.
PURPOSE OF REVIEW: The treatment of acute lymphoblastic leukemia (ALL) in adolescent and young adult (AYA) patients has markedly improved with the adoption of pediatric-inspired protocols. However, there remain several subtypes of ALL that represent significant therapeutic challenges. Here, we review the current evidence guiding treatment of Philadelphia chromosome-positive (Ph+), Philadelphia chromosome-like (Ph-L), and early T-precursor (ETP) ALL in the AYA population. RECENT FINDINGS: Clinical trials in Ph + ALL have demonstrated the superior efficacy of second- and third-generation tyrosine kinase inhibitors (TKIs) to induce and maintain remission. Current efforts now focus on determining the durability of these remissions and which patients will benefit from transplant. For Ph-like and ETP ALL, recent studies are investigating the addition of novel agents to standard treatment. The treatment of Ph + ALL has significantly improved with the addition of potent TKIs. However, the treatment of Ph-like and ETP ALL remains a challenge. At this time, the judicious use of allogenic transplant is the only current approach to modify this increased risk.
Authors: Miriam Frech; Lutz B Jehn; Kathleen Stabla; Stephan Mielke; Björn Steffen; Hermann Einsele; Stephan K Metzelder; Andreas Neubauer Journal: Haematologica Date: 2017-01-05 Impact factor: 9.941
Authors: D J DeAngelo; K E Stevenson; S E Dahlberg; L B Silverman; S Couban; J G Supko; P C Amrein; K K Ballen; M D Seftel; A R Turner; B Leber; K Howson-Jan; K Kelly; S Cohen; J H Matthews; L Savoie; M Wadleigh; L A Sirulnik; I Galinsky; D S Neuberg; S E Sallan; R M Stone Journal: Leukemia Date: 2014-07-31 Impact factor: 11.528
Authors: Amy M Berkman; Clark R Andersen; Branko Cuglievan; David C McCall; Philip J Lupo; Susan K Parsons; Courtney D DiNardo; Nicholas J Short; Nitin Jain; Tapan M Kadia; J A Livingston; Michael E Roth Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-06-01 Impact factor: 4.090